Trinity Capital, an international alternative asset manager, invested $35 million in Neuros Medical, developer of the Altius Direct Electrical Nerve Stimulation System that interrupts peripheral nerve signals responsible for phantom limb and residual limb pain. The new capital will help the company scale the commercialization of Altius and expand into new markets.
Altius was approved by the US Food and Drug Administration in 2024.
“Neuros Medical has reached an important inflection point as their technology moves into real-world adoption,” said Rob Lake, senior managing director, life sciences, Trinity Capital. “We are proud to continue to support their team as they expand access to a differentiated therapy that addresses a significant need within the life sciences ecosystem.”
“We appreciate the continued partnership from Trinity,” said David Veino, president and CEO, Neuros Medical. “The Trinity team has been an important partner prior to us achieving FDA approval and will remain an important partner as we expand. This expansion of our debt facility provides important financial flexibility as Neuros enters the next phase of its mission to relieve pain and restore life for this underserved patient population.”
